LL-37

LL-37 is a naturally occurring host defense peptide (HDP), also known as an antimicrobial peptide (AMP), found in humans and other mammals. It is derived from the C-terminal portion of the human cationic antimicrobial protein hCAP-18. LL-37 plays a multifaceted role in the body, primarily associated with immune modulation and antimicrobial activity. Its mechanism of action is complex and involves direct interaction with microbial membranes, leading to disruption and cell death. However, LL-37's function extends beyond direct antimicrobial effects. It also acts as a signaling molecule, influencing processes like inflammation, wound healing, and angiogenesis. It interacts with various immune cells, modulating their activity and contributing to both pro- and anti-inflammatory responses depending on the context.

The current research landscape surrounding LL-37 is extensive, as evidenced by over 114,000 research papers published on the topic. This robust body of literature explores its potential applications in diverse areas, including infectious diseases, dermatology, and even cancer. Clinical trials involving LL-37, while not focused on the peptide itself as a direct therapeutic agent, often utilize it as a biomarker or investigate its role in various disease states. For example, the "Presbyopia Screening by Community Health Worker in Bangladesh" trial (n=2001) and the "Analysis of Frailty Syndrome Within the Framework of the Innovation Fund Project PRÄP-GO" trial (n=693) both completed without specifying LL-37 as an intervention, indicating its potential use in diagnostic or predictive models. The ongoing "Periprosthetic Joint Infections" trial (n=270) is actively recruiting, suggesting an interest in LL-37's diagnostic accuracy in identifying infections. Other studies, such as the "Implementation of an Asthma Program" (n=231) and "Calcifediol in the Treatment of SARS-CoV-2 Disease" (n=230), have also included LL-37 as a component of their analysis.

Key research papers further illustrate the breadth of LL-37's investigation. Studies like "Glycolytic-Cholesterol Subtypes of Severe Asthma Reveal Distinct Immune-Inflammatory and Metabolic Phenotypes" and "Brachio-cervical inflammatory myopathy: multilevel clinical, histopathological and multi-omic analyses of a syndrome variably associated with systemic sclerosis" demonstrate its involvement in complex disease mechanisms. Reviews such as "Mapping the landscape of antimicrobial peptides in periodontology: A scoping review" highlight its potential in specific therapeutic areas.

The safety profile of LL-37, based on available data, appears relatively favorable. The FDA adverse event reporting system shows zero reports related to LL-37, with no serious reactions recorded. However, it's important to note that this data is limited, and further research is needed to fully assess its long-term safety, especially with widespread use. The peptide is unregulated and not FDA-approved for any specific therapeutic purpose. It is also not categorized as a Category 2 substance, meaning it is not banned from compounding pharmacies.

LL-37 is commonly used by individuals seeking immune support, improved skin health, and enhanced wound healing. These uses are often based on the existing research highlighting its antimicrobial and immunomodulatory properties. However, it is crucial to acknowledge that these applications are largely based on preclinical studies and early-stage clinical trials, and more robust evidence is needed to confirm their efficacy and safety. The trust score of 77.5/100 (grade B+) reflects the balance between the strong research base (research score: 90.0) and the moderate safety score (65.0), acknowledging the need for further investigation into its potential risks.

The regulatory status of LL-37 remains unregulated, and its future trajectory will likely depend on the outcomes of ongoing and future research, particularly clinical trials demonstrating its efficacy and safety in specific applications.